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NT-proBNP is a biomarker of cardiovascular disease (CVD). Little is known about the herita-
bility and genetic variants associated with NT-proBNP. Therefore, we estimated the herita-
bility of and examined genetic associations of SNPs in the BNP gene region with circulating
NT-proBNP and prevalent CVD in 4,331 participants from the Long Life Family Study
(LLFS).
Methods and results
Genotypes of 10 SNPs from the NPPB and NPPA regions that encode BNP and A-type
natriuretic peptide, respectively, were tested for association with NT-proBNP and prevalent
cardiovascular disease and risk factors. We performed analyses using the Sequential Oligo-
genic Linkage Analysis (SOLAR) program to account for family relatedness, and adjusted
all models for age, sex, and field center. The mean age of the LLFS was 69.8 years (range
24–110) with 55.4% females. NT-proBNP was significantly heritable (h2 = 0.21; P = 4x10-
14), and the minor alleles of rs632793 (p<0.001) and rs41300100 (p = 0.05) were indepen-
dently associated with higher serum NT-proBNP levels. Additionally, the minor allele of
rs632793 was significantly and consistently associated with lower prevalent CVD, including
blood pressures, independent of NT-proBNP level (all P<0.05). Results for prevalent CVD,
but not NT-proBNP levels, showed significant interaction by familial generation.
Conclusion
In this family-based study of subjects with exceptional longevity, we identified several allelic
variants in the BNP gene region associated with NT-pro-BNP levels and prevalent CVD.
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Introduction
Cardiovascular disease (CVD) is the leading cause of death globally [1]. B-type natriuretic pep-
tide (BNP) has been established as a diagnostic biomarker for heart failure (HF), a subset of
CVD [2]. BNP has also been associated with established risk factors for CVD including hyper-
tension [3], obesity [4] and diabetes [5]. The natriuretic peptide family consists of three pep-
tides: atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic
peptide. BNP is released as a pro-hormone (proBNP), and proBNP comprises 108 amino
acids, which can be cleaved into two parts: N-terminal fragment proBNP (AA residues 1–76;
NT-proBNP), and C-terminal BNP (AA residues77-108) [6]. NT-proBNP persists in the circu-
lation longer, has a higher concentration in plasma, and is more stable in vitro compared to
the full length or C-terminal BNP, which makes NT-proBNP a better clinical biomarker [7].
Cardiomyocyte stretch during abnormal intracardiac pressure is the primary stimulus for
BNP expression [8]. As such, circulating BNP serves as a compensatory mechanism to offset
the excessive vascular vasoconstriction when there is a decreased pumping capacity of the
heart. NT-proBNP levels are used clinically to predict the risk of CVD, diagnose heart failure
(HF), and to monitor the prognosis of other CVDs [3, 9, 10]. A diagnosis of HF can be ruled
out if with age-specific low NT-proBNP levels in the non-acute setting, as established by the
2016 European Society of Cardiology guidelines [9]. Specifically, the normal range of NT-
proBNP is<125pg/ml in individuals aged<75 years, and<450pg/ml in individuals aged
�75years [11].
However, little is known about the genetic determinants of BNP with only a handful of
studies evaluating its genetic regulation [12] and only a single study reporting its genetic heri-
tability [13]. The study of heritability included 1,914 Framingham Heart Study participants
from which they estimated the heritability of NT-proBNP to be 0.35 after adjustment for age,
sex, and clinical variables [13]. Several single nucleotide polymorphisms (SNPs) in the NPPB
gene region have been associated with NT-proBNP levels and CVD outcomes in population
studies [14, 15] and clinical studies of patients with coronary artery disease [16].
In the current study, we aimed to replicate and extend results from a previous study con-
ducted in the Atherosclerotic Risk in Communities (ARIC) cohort [15], of the association of
prevalent CVD conditions with common genetic variation in the BNP gene region. Like previ-
ous studies, we focused on common, independent genetic variation in the NPPA/NPPB region,
two genes that lie in close proximity to each other and encode for ANP and BNP, respectively.
In addition, we expanded on previous findings from ARIC by conducting analyses in generally
healthy adults from a unique set of families recruited for exceptional longevity, the Long Life
Family Study (LLFS). Compared to ARIC, LLFS is older (69.8 ± 15.5 vs. 54.3 ± 6) with a wider
age range (24–110 vs. 45–64), and has a lower prevalence of hypertension. Therefore, not only
is the LLFS a sample of individuals at low risk for their age of severe CVDs like HF, but the
wide age range also allows for determination of how results may differ by age–a known strong
correlate of NT-proBNP levels [17].
Methods
Population
The Long Life Family Study (LLFS) is a family-based multi-center cohort study that enrolled
4,953 predominantly European-ancestry participants between 2006 and 2009 from 539 fami-
lies with exceptional longevity [18]. Participants were recruited at four study centers: Boston,
MA (Boston University), New York, NY (Columbia University), Pittsburgh, PA (University of
Pittsburgh), and Denmark (University of Southern Denmark). Potential probands in the US
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who were at least 79 years old on January 1, 2005, and who had no end-stage renal disease or
residence in hospice programs, were pre-screened for eligibility by telephone [18]. In Den-
mark, individuals who would be aged 90 and above during the study recruitment period were
identified through the Danish National Register of Persons, which contains current informa-
tion on names, addresses, place of birth, marriages, and vital status, and linked to archived par-
ish registers to identify sibships. Eligibility at all centers was assessed by calculating a Family
Longevity Selection Score (FLoSS), which was built from the birth date, gender, nation-specific
cohort survival probabilities and the number of older living siblings [19]. A FloSS score of 7 or
higher was required for a family to be eligible as long as they also met the following criteria:
the proband and at least one living sibling and one of their living offspring were willing to par-
ticipate in the LLFS interview and provide a blood sample [18].
All baseline LLFS interviews and examinations were conducted in person with portable
equipment. All research assistants conducting the exams were centrally trained and certified,
and used standard protocols. Copies of all LLFS forms are provided with this manuscript as
Supporting Information. The current analysis was done on a subset of 4,331 LLFS participants
after excluding 622 participants who were missing serum NT-proBNP measures or measures
under the assay detection limit of 5pg/ml (N = 335) or was an outlier (BNP = 27950, N = 1),
had current and/or a history of heart failure (N = 218), and those with missing pedigree data
(N = 68). Written informed consent was obtained from each LLFS participant, and all study
forms and protocols were approved by the Institutional Review Boards at Boston University,
Columbia University, and the University of Pittsburgh, and by the Research Ethics Committee
at the University of Southern Denmark.
Measurement of NT-proBNP
Blood samples were collected after a�6-hour fast and were shipped on ice within 48 hours to
the LLFS central blood laboratory at the University of Minnesota for storage at -80˚C until
assays were completed. Serum NT-proBNP was measured at baseline in the central laboratory
by a Roche e411 Analyzer, which applies the sandwich immunoassay method to quantify NT-
proBNP (Roche Diagnostics, Indianapolis, IN). The NT-proBNP inter-assay coefficient of var-
iation (CV) was 2.7% at a mean concentration of 139.9 pg/mL and 5.1% at a mean concentra-
tion of 4,707.3 pg/mL.
Genotyping
Genomic DNA was extracted from peripheral blood samples at the LLFS central blood labora-
tory at the University of Minnesota and shipped to the LLFS central genomics laboratory at
the University of Washington St. Louis for genotyping. All genotype data from the LLFS were
obtained from the Human Omni 2.5 v1 (Illumina, CA) genotyping chip, which was used on
genomic DNA extracted from peripheral blood samples. In order to replicate previous studies
and have enough power to detect associations with multiple comparisons, we focused on SNPs
located within the genomic region spanning from the 5’ end of NPPA through the 3’ end of
NPPB, which encode for ANP and BNP, respectively, and lie next to each other on chromo-
some 1. Both NPPB and NPPA regions were considered since there is evidence that these two
genes share common regulatory sequences [20]. In total, 20 SNPs were directly genotyped in
this region on the OMNI Chip. We excluded SNPs whose total number of heterozygotes
+ minor homozygotes was <10 (N = 5) and selected 1 SNP at random for each set of SNPs
with linkage disequilibrium (LD)>0.8 (N = 5 excluded; Fig 1). After these exclusions, 10
SNPSs were selected for analysis. We coded the remaining SNPs as 0, 1, 2 based on the number
of minor alleles. If the number of minor homozygous genotypes was <10, then we combined
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the minor homozygote genotype with the heterozygote genotype in order to increase power
(N = 4; Table 1).
Other measurements
Standing height was measured to the nearest 0.1 cm with a Handi-stat set square (Perspective
Enterprises, Portage, MI) and the average of four measurements was used in analysis. Weight
was measured to the nearest 0.1 kg with an electronic digital scale (SECA 841, Hanover, MD).
Body mass index (BMI) was calculated from these measurements as weight (kg)/height (m)2.
Centrally trained research assistants measured sitting blood pressure using the average of three
Fig 1. Linkage disequilibrium in the NPPB/NPPA gene region in the LLFS. Pairwise linkage disequilibrium (LD) in
the LLFS was calculated and plotted using the gaston package in R for all genotyped SNPs in the BNP gene regions. R2
values are shown and depicted using a heatmap function. Independent SNPs selected for this analysis are underlined.
https://doi.org/10.1371/journal.pone.0248726.g001
Table 1. Description of genotyped SNPs in the NPPA/NPPB gene region.













rs198358 11844019 A/G 2545 (59.4) 1500 (35.0) 243 (5.7) 0.23 Additive
rs5068 11845917 T/C 3843 (89.4) 440 (10.2) 15 (0.4) 0.05 Additive
rs5065 11846011 A/G 3187 (74.1) 996 (23.2) 117 (2.7) 0.14 Additive
rs5063 11847591 G/A 3906 (90.8) 382 (8.9) 12 (0.3) 0.05 Additive
rs41300100 11848089 C/G 4218 (98.3) 74 (1.7) 1 (0.02) 0.01 Dominant
rs17376426 11848110 C/T 3999 (93.0) 296 (6.9) 3 (0.1) 0.04 Dominant
rs198372 11849457 G/A 3166 (73.6) 1029 (24.0) 105 (2.4) 0.14 Additive
rs632793 11850620 A/G 1488 (34.6) 2082 (48.4) 728 (16.9) 0.41 Additive
rs6541007 11857407 G/A 4119 (95.8) 180 (4.2) 2 (0.05) 0.02 Dominant
rs5229 11858462 G/A 4179 (98.1) 82 (1.9) 0 (0.0) 0.01 Dominant
�sorted in 5’ to 3’ direction based on human genome GRCh38.p13.
https://doi.org/10.1371/journal.pone.0248726.t001
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readings from an automated blood pressure machine (BP-tru BPM 300, VMS Medtech,
Coquitlam, Canada). Hypertension was defined as SBP� 130 mmHg or DBP� 80 mmHg
during the LLFS examination or current use of anti-hypertension medication [18]. Participant
history of (atrial fibrillation) AF and myocardial infarction (MI) were determined by self-
report during the interview process and included collection of information regarding treat-
ment or hospitalization, if applicable.
Statistical analysis
All analyses were performed using the Sequential Oligogenic Linkage Analysis (SOLAR) pro-
gram, which applies a variance-covariance method to adjust for family structure [21]. We
defined outliers for NT-proBNP as +/- 4SD from the mean and excluded one observation
(value = 27,950 pg/ml). We then log-transformed the NT-proBNP values to conform to the
assumption of normal distribution as required by the SOLAR program. All analyses were
adjusted for age, sex, and field center and used an alpha of 0.05 as a threshold for nominal
significance, but also assessed Bonferroni-corrected alpha levels, as described below. Other
potential risk factors for CVD, such as BMI, smoking, lipoprotein levels, and diabetes were
considered to be potentially in the causal pathway and were not included as adjustment factors
in order to not over-adjust the associations. We used multiple linear regressions to test
the association of our selected SNPs (predictors) and logNT-proBNP (outcome), first as indi-
vidual SNPs and then as SNPs combined into a single model in order to identify SNPs with
independent associations with NT-proBNP (Bonferroni corrected alpha for 10 SNPs = 0.005).
We tested the association of SNPs that were associated with NT-proBNP level with individ-
ual CVD related measures and risk factors (Bonferroni corrected alpha for 7 SNPs = 0.007)
including blood pressures, prevalent hypertension, BMI, history of AF, and history of MI.
Lastly, for all significant models after Bonferroni correction, we ran additional analyses includ-
ing adjustment for NT-proBNP level in order to determine if the significant genetic association
was partially driven by NT-proBNP level itself. We also conducted sensitivity analyses among
individuals of either generation who had NT-proBNP levels in the normal range defined as:
<125pg/ml in those aged<75 years, and<450pg/ml in individuals aged�75years (N = 3,309)
[22]. Lastly, given the wide age range and global distribution of the LLFS, we also performed
stratified analyses and tested for interaction by familial generation (proband generation and
offspring generation) and country (US versus Denmark).
Results
Characteristics of LLFS population
The 4,331 participants from the LLFS in this analysis consisted of 55.4% females and were
aged 69.8 years (24–110) on average (Table 2). Of the 4,331 participants, 1,385 were in the pro-
band generation (49–110), while 2,946 were in the offspring generation (24–88). Approxi-
mately 6% of participants had a history of AF and 5% had a history of MI. The average systolic
blood pressure (SBP) and diastolic blood pressure (DBP) were 131.8 mmHg and 77.5 mmHg,
respectively. 55% percent of participants had hypertension and 80% were on anti-hypertensive
therapy. The median level of NT-proBNP was 86 pg/ml. After adjusting for age, sex, and field
center, the residual heritability of NT-proBNP was 0.21 (p = 4 × 10−14).
Associations of SNPs with NT-proBNP level
Genotype information for the 10 SNPs in the NPPA/NPPB region used in this analysis are
listed in Table 1. Seven of these SNPs showed nominally significant associations with NT-
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proBNP level (all P<0.05; Table 3). Entered together into a single model, these 7 SNPs
accounted for 0.85% of the variance in NT-proBNP level. However, only 2 SNPs were indepen-
dently associated with NT-proBNP level: rs632792 (additive β = 0.16, p<0.001) and
rs41300100 (dominant β = 0.26, p = 0.05; Table 3). On average, for each copy of the G allele at
rs632793, individuals had 3.5% greater NT-proBNP than individuals with the AA genotype.
Additionally, individuals with 1 or more A allele at rs41300100 had 5.7% greater NT-proBNP
than those with the GG genotype.
Table 2. Basic characteristics of the LLFS by generation.
Characteristic All LLFS Proband Generation Offspring Generation
Total Participants 4331 1385 2946
Age (mean ± SD) 69.8 ± 15.5 89.2 ± 6.9 60.6 ± 8.3
Female n (%) 2398 (55.4) 755 (54.51) 1643 (55.8)
Field Center n (%) Denmark 1163 (26.9) 203 (14.7) 960 (32.6)
Boston 1165 (26.9) 367 (25.5) 798 (27.1)
New York 863 (19.9) 408 (29.5) 455 (15.4)
Pittsburgh 1140 (26.3) 407 (29.4) 733 (24.9)
BMI (kg/m2) mean ± SD 27.1 ± 4.8 26.1 ± 4.2 27.5 ± 4.9
SBP (mmHg) mean ± SD 131.8 ± 22.2 139.2 ± 25.3 128.4 ± 19.7
DBP (mmHg) mean ± SD 77.5 ± 11.4 74.0 ± 11.7 79.1 ± 10.9
Hypertension n (%) 3166 (73.1) 1189 (85.9) 1977 (67.1)
Diabetes n (%) 300 (6.9) 131 (9.5) 169 (5.7)
Atrial Fibrillation n (%) 242 (5.6) 175 (12.7) 67 (2.3)
Myocardial Infarction n (%) 213 (4.9) 129 (9.3) 84 (2.9)
NT-proBNP (pg/ml) median (range) 86.0 (5–14739) 341 (5–14739) 54 (5–5310)
BMI: Body Mass Index, NT-proBNP: N-Terminal pro-BNP, SBP: Systolic Blood Pressure, DBP: Diastolic Blood Pressure.
https://doi.org/10.1371/journal.pone.0248726.t002
Table 3. Association between SNPs and NT-proBNP level.
SNPs Univariate Independently Significant SNP
β P-value β P-value
rs198358 0.11 <0.001� -0.03 0.43
rs5068 0.12 0.01 0.06 0.33
rs5065 0.03 0.31
rs5063 0.24 <0.001� 0.13 0.06
rs41300100 0.47 <0.001� 0.26 0.05
rs17376426 0.12 0.04 -0.09 0.14
rs198372 0.06 0.04 -0.02 0.6
rs632793 0.17 <0.001� 0.16 <0.001�
rs6541007 -0.05 0.55
rs5229 -0.03 0.82
NT-proBNP was modeled as the outcome and the SNPs were the predictors, adjusting for age, sex, study center. For Univariate results, each SNP was tested alone in a
single model. Then SNPs that were significant in Univariate analyses were combined together into a single model to determine SNPs with independent effects on NT-
proBNP level.
BOLD signifies P<0.05
�denotes passing Bonferroni correction threshold.
https://doi.org/10.1371/journal.pone.0248726.t003
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Association of NT-proBNP with prevalent CVD measures
Associations between NT-proBNP level and CVD related measures are shown in S1 Table.
NT-proBNP level was positively associated with age (p = 1 × 10−307), such that a 1 unit greater
logNT-proBNP (~2.72 pg/ml) was associated with ~8 years greater age after adjusting for sex
and study center. After adjusting for age and study center, 1 log(pg/ml) increased logNT-
proBNP was associated with 20% greater odds of being male (P = 1×10−17). After full adjust-
ment for age, sex, and study center, 1 unit increased NT-proBNP was associated with 0.53
mmHg decreased diastolic blood pressure (p = 0.002), 0.12 kg/m2 decreased BMI, 45%
decreased odds of having AF history, and 22% decreased odds of MI history (all P<0.001).
Association of SNPs with prevalent CVD measures
Associations between the 7 SNPs individually associated with NT-proBNP levels and CVD
measures are shown in Table 4. The minor allele of rs632793 was nominally associated with
AF, such that the presence of each G allele was associated with an additional 10% lower odds
of a history of AF compared to individuals with the AA genotype (P = 0.030). Also, the minor
(G) allele of rs632793 was associated with lower SBP (β = -1.3, p = 0.0095) and DBP (β = -0.6,
p = 0.018), but no significant association with prevalent hypertension when defined by blood
pressures or medication status (p = 0.807).
After further adjusting significant associations for NT-proBNP level, the association
between the minor allele of rs632793 and AF was attenuated (β = -0.07; p = 0.180), while its
associationwith lower SBP and DBP remained significant (P<0.04; S5 Table). In sensitivity
analyses conducted only in individuals with NT-proBNP levels in the normal range
(N = 3309), the results were largely similar for all analyses (S2–S4 Tables).
Stratified analyses
Compared to the proband generation, the offspring generation had a greater number of signif-
icant associations between SNPs and NT-proBNP level (Table 5). In addition to rs632793,
rs17376426 was significantly and independently associated with NT-proBNP levels in the off-
spring generation. While there was significant interaction by generation for rs198358 and
rs5065 (both Pinteraction <0.05), the effect of rs632793 on levels of NT-proBNP was similar
across generations (Pinteraction = 0.09). However, the associations of SNPs with CVD measures
(Table 6) were predominantly seen in the proband generation, without any significant findings
in the offspring who had less CVD burden in general (Table 2). Similar to results in all LLFS,
Table 4. Association between CVD measures and SNPs associated with BNP level.
SNP BMI SBP DBP Hypertension AF MI
β P β P β P β P β P β P
rs198358 -0.04 0.15 0.14 0.8 -0.04 0.9 0.03 0.39 -0.09 0.09 -0.02 0.7
rs5068 0.02 0.64 -1.05 0.32 0.21 0.7 0.04 0.53 -0.14 0.18 0.02 1
rs5063 -0.06 0.27 0.36 0.75 -0.9 0.13 -0.01 0.9 0.05 0.69 -0.1 0.37
rs41300100 0.07 0.57 -1.08 0.67 -0.78 0.56 -0.07 0.7 -0.07 0.79 0.36 0.23
rs17376426 0.04 0.54 -0.22 0.87 0.93 0.17 -0.01 0.88 -0.01 0.93 0.02 0.98
rs198372 -0.03 0.44 -0.64 0.34 -0.4 0.25 0.03 0.55 -0.01 0.89 -0.03 0.69
rs632793 -0.02 0.36 -1.25 0.01 -0.59 0.018 0.01 0.81 -0.11 0.03 0 0.89
Adjusted for age, sex, and study center.
BOLD signifies P<0.05.
https://doi.org/10.1371/journal.pone.0248726.t004
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rs632793 was inversely associated with SBP and DBP, although the association with AF was
not significant in either single generation subset (Table 6). These generation-specific effects
for rs632793 are suggestive of a significant interaction by generation on blood pressures
(Pinteraction<0.05; S6 Table). Additionally, rs41300100 was significantly associated with hyper-
tension (β = -4.06, p = 0.006, Table 6) in the proband generation, alone; however this effect did
not reflect significant interaction by generation (S6 Table).
Analyses stratified by study center (US versus Denmark) demonstrated similar population
characteristics by country (S7 Table). Results were also consistent by country for the associa-
tion of rs632793 and rs41300100 with NT-proBNP level (S8 Table) and showed no significant
interaction effect by country on the association of BNP SNPs and CVD measures. However,
the association between rs632793 and AF appears to be driven by families at the Danish study
center (S8 Table).
Table 5. Association of BNP variants with NT-proBNP level stratified by LLFS generation.
SNPs Proband Generation Offspring Generation Interaction
β P-value β P-value P-value
rs198358 0.006 0.9 0.16 <0.001 0.01
rs5068 0.03 0.71 0.16 0.003 0.25
rs5065 -0.08 0.15 0.08 0.03 0.03
rs5063 0.28 0.004 0.25 <0.001 0.84
rs41300100 0.45 0.05 0.47 <0.001 0.85
rs17376426 0.18 0.17 -0.21 0.002� 0.08
rs198372 -0.03 0.64 0.09 0.007 0.13
rs632793 0.1 0.01� 0.19 <0.001� 0.09
rs6541007 -0.06 0.7 0.04 0.62 0.41
rs5229 -0.08 0.66 -0.04 0.78 0.90
All models adjusted for age, sex, and study center.
� Indicates SNPs with independent effects after combining SNPs with individual P-value<0.1 together into a single model.
https://doi.org/10.1371/journal.pone.0248726.t005
Table 6. Association of BNP variants with CVD measures stratified by LLFS generation.
NT-proBNP Associated SNP BMI SBP DBP Hypertension AF MI
β P β P β P β P β P β P
Proband
rs5063 -0.08 0.38 2.02 0.4 -1.3 0.25 -0.32 0.06 -0.09 0.57 -0.16 0.32
rs41300100 -0.13 0.56 0.64 0.91 -0.46 0.86 -4.06 0.006� -0.23 0.49 0.42 0.34
rs632793 0.02 0.55 -2.72 0.007� -1.42 0.003� -0.06 0.34 -0.08 0.22 0.01 0.92
Offspring
rs198358 -0.05 0.1 0.78 0.19 0.31 0.36 0.04 0.35 -0.14 0.11 -0.06 0.48
rs5068 0.06 0.31 -0.54 0.63 0.5 0.43 0.03 0.75 -0.19 0.22 -0.09 0.53
rs5065 -0.06 0.12 1.01 0.15 0.31 0.43 0.01 0.87 -0.17 0.08 -0.01 0.89
rs5063 -0.08 0.2 0.1 0.93 -0.52 0.43 0.06 0.49 0.3 0.14 -0.04 0.93
rs41300100 0.14 0.34 -0.62 0.82 -0.57 0.71 0.05 0.78 0.22 0.6 0.33 0.46
rs17376426 0.05 0.51 -0.05 0.97 0.72 0.33 -0.01 0.93 0.002 0.99 -0.04 0.84
rs198372 -0.04 0.33 0.06 0.93 -0 0.99 0.03 0.6 -0.11 0.29 0.04 0.72
rs632793 -0.04 0.16 -0.72 0.15 -0.24 0.39 0.03 0.35 -0.14 0.07 0.01 0.85
All models adjusted for age, sex, and study center.
� Indicates an association that remained significant (P<0.05) after further adjustment for NT-proBNP level.
https://doi.org/10.1371/journal.pone.0248726.t006
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Discussion
We found that, in the LLFS, NT-proBNP was significantly heritable (residual heritability esti-
mate (H2r) = 0.21) and that there were 7 SNPs in the NPPA/NPPB region associated with NT-
proBNP level. The minor alleles of rs632793 and rs41300100 were independently associated
with higher NT-proBNP level. Additionally, NT-proBNP was positively associated with age
and male sex, but negatively associated with BMI, blood pressure, AF, and MI. The minor
allele of rs632793 was inversely associated with SBP, DBP, and a history of AF. The significant
association of SNPs with blood pressures was independent of NT-proBNP level, which may
suggest that not all of the genetic association was explained by NT-proBNP level, though longi-
tudinal analyses would be needed to determine this for certain. Lastly, results with prevalent
CVDs also showed an interaction with age group (i.e., generation); thereby, highlighting the
age-related differences in BNP function.
These results are consistent with previous findings that NT-proBNP is heritable (previous
evidence H2r = 0.34) [13] and that common SNPs in the NPPA/NPPB region are associated
with circulating NT-proBNP level [15, 16, 23, 24]. Our results are also similar to previous stud-
ies showing that NT-proBNP is positively associated with age [25] and inversely associated
with BMI [26]. We identified rs632793 as the most significant and consistent genetic variant
associated with NT-proBNP level in the total LLFS, as well as, in the proband generation
alone. This is in line with previous studies [14, 16, 27, 28], although, some other studies
focused specifically and solely on rs198389 [15, 16, 24, 29–31]. These two variants are in strong
LD in our study (Fig 1) and; thus, likely represent the same underlying genetic signal.
The somewhat counterintuitive association between SNPs in this region being associated
with higher circulating NT-proBNP levels, but lower risk of cardiovascular conditions and risk
factors even though higher NT-proBNP is associated with increased CVD risk, is consistent
with previous reports [14, 16, 32–34]. The physiologic function of BNP is to relieve the heart of
excess stress by reducing vascoconstriction [8, 35], so it plays a protective role in early life. But
in the presence or progression of cardiac disease, the body is required to up-regulate the
expression of BNP in order to attempt to relieve the symptoms of disease [15] and which is in
line with associations we saw between NT-proBNP level and CVD risk factors in the current
study (S1 Table). This is why greater circulating BNP is indicative of disease and can be used
as a clinical marker of HF diagnosis or progression. Interestingly, our interaction analyses
showed that the genetic associations did not significantly differ by generation (i.e. aging) for
NT-proBNP level, but did for blood pressure and hypertension. This also supports the hypoth-
esis that the counterintuitive direction of effect is not driven by genetic effects, but rather by
the body’s regulation of NT-proBNP levels in relation to progression of cardiovascular disease.
The goal of the current study was to replicate and extend findings on BNP genetics and
CVD that exist in the literature. However, it is unique to previous reports in that our families
largely consist of exceptionally healthy, older adults with a low burden of CVD for their age
compared to previous studies in high-risk groups. In the LLFS, we found that rs632793 which
was associated with greater NT-proBNP level, was also associated with lower prevalence of car-
diovascular conditions and risk factors. This relationship demonstrates the physiologic protec-
tive role of BNP across age groups and even in generally healthy adults, which suggests the
relationships are not driven by a predisposition to a high risk of CVD. This idea is even more
clear from the sensitivity analyses in individuals with normal NT-proBNP levels, which
showed similar results to the whole LLFS cohort. This observation warrants further study of
the clinical utility for CVD risk prediction of NT-proBNP in low-risk populations.
The results of the current study identified SNPs that have previously been reported to be
associated with NT-proBNP and/or CVD: primarily rs632793 (in LD with rs198389), but also
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rs41300100 and rs17376426. While the function of rs632793 is not known, it is located in the
5’ flanking promoter region and is predicted to be associated with transcription regulation
[36]. Also, rs198389 (in LD with rs632793) is located in an upstream regulatory region of
NPPB and the minor (G) allele has been shown to be associated with 1.8-fold higher NPPB
promoter activity [32]. rs198389 has been associated with higher NT-proBNP and BNP levels
[12, 15, 16, 23, 24, 32–34, 37], lower blood pressure and hypertension [15] and a reduced rate
of cardiovascular readmission [16].
In addition to rs632793, rs41300100 was associated with NT-proBNP level in all LLFS and
hypertension in the proband generation, and rs17376426 was associated with NT-proBNP
level independent of rs632793 in the offspring generation. rs41300100 is located in the 5 prime
UTR of NPPA, and is predicted to lie in an enhancer region [38]. However, this particular SNP
is not in LD with any other SNP in the region in the LLFS (Fig 1) and has not been reported to
be associated with any traits to date. rs17376426 is located at 2KB upstream transcript variant
and is predicted as a regulatory variant [39]. Therefore, the potential functional impact of
rs41300100 and rs17376426 on NT-proBNP levels and/or function is unknown, and may war-
rant further investigation.
This study has several strengths. First, the LLFS provided a wide age range of adults to test
the genetic association of BNP and is the first study to conduct these analyses in exceptionally
long-lived individuals at low-risk for CVD. While the exceptional longevity and healthier than
age-matched indivudals of the LLFS may make it seem like it is not generalizable, there is still
substantial chronic disease prevalence and a wide variation in all measures of health within the
cohort [18]. Additionally, the family study design of LLFS allowed us to calculate the heritabil-
ity of NT-proBNP and is only the second study to do so. There was also a reasonably large
sample size (N = 4,331) for a candidate gene approach and we used the most reliable assay for
NT-proBNP measurement. We also assessed our primary results using both a nominal
(P�0.05) and Bonferroni-corrected P-value threshold given our strong a priori hypotheses
and limited scope of work. Lastly, we looked at multiple SNPs across the NPPA/NPPB region
instead of only a single candidate SNP, as many previous reports of rs198389 have done [15,
23, 24, 33, 40, 41]. This approach allowed for the identification of a number of SNPs in addi-
tion to rs198389 with significant associations to either NT-proBNP or CVD, that would have
otherwise been missed.
However, there are a number of additional considerations. We do not yet have longitudinal
data on NT-proBNP or incident cardiovascular disease risk in the LLFS; however, as the study
continues follow-up, we will be able to assess these in the future. As age is a strong, non-linear
determinant of NT-proBNP level, the inclusion of a wide-range of ages may have attenuated
our associations between genetic variants and NT-proBNP given the variation in risk predic-
tion by CVD status. However, our sensitivity analyses in individuals with normal NT-proBNP
levels attempted to minimize the influence of prevalent cardiac disease. Besides, we limited our
study to SNPs in the NPPA/NPPB region on chromosome 1. We did this in order to look at
the association of genetic variation around BNP with circulating BNP levels and only looked at
common SNPs in order to minimize the number of tests. However, SNPs in other regions,
such as rs11105306 located on chromosome 12 and rs13107352 located on chromosome 4,
have also been shown to be associated with the circulating NT-proBNP levels [30], which we
did not assess in the current study. In addition, there are a number of factors that were not
included in our analyses as they were considered to potentially be a part of the causal pathway
between BNP and CVD, including BMI, smoking, lipids, and diabetes. However, it is likely
that these factors are involved in the reported relationships. Lastly, while we did not include a
replication cohort, we started with an a priori hypothesis to do a candidate gene association
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study and our results were in-line with previous reports; thus, our study serves as replication
to this previous work.
We found that NT-proBNP level is significantly heritable in a cohort of families with excep-
tional aging: the LLFS. We also identified rs632793, rs41300100, and rs17376426 to be inde-
pendently associated with NT-proBNP levels and related prevalent CVD conditions and risk
factors. We showed that alleles associated with greater NT-proBNP were also associated with a
lower prevalence of CVD conditions and risk factors, even though high NT-proBNP levels are
used clinically to indicate heart failure. This seemingly counterintuitive result is consistent
with previous reports and highlights the complex relationship and negative feedback loop of
the BNP protein and cardiovascular conditions. As such, future research may benefit from tak-
ing into consideration genetic determinants when evaluating clinical use of BNP in the aging
population.
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